James A Heslop1, Stephen A Duncan1. 1. Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC.
Abstract
The use of pluripotent stem cells (PSCs) has transformed the investigation of liver development and disease. Clinical observations and animal models have provided the foundations of our understanding in these fields. While animal models remain essential research tools, long experimental lead times and low throughput limit the scope of investigations. The ability of PSCs to produce large numbers of human hepatocyte-like cells, with a given or modified genetic background, allows investigators to use previously incompatible experimental techniques, such as high-throughput screens, to enhance our understanding of liver development and disease. In this review, we explore how PSCs have expedited our understanding of developmental mechanisms and have been used to identify new therapeutic options for numerous hepatic diseases. We discuss the future directions of the field, including how to further unlock the potential of the PSC model to make it amenable for use with a broader range of assays and a greater repertoire of diseases. Furthermore, we evaluate the current weaknesses of the PSC model and the directions open to researchers to address these limitations. Conclusion: The use of PSCs to model human liver disease and development has and will continue to have substantial impact, which is likely to further expand as protocols used to generate hepatic cells are improved.
The use of pluripotent stem cells (PSCs) has transformed the investigation of liver development and disease. Clinical observations and animal models have provided the foundations of our understanding in these fields. While animal models remain essential research tools, long experimental lead times and low throughput limit the scope of investigations. The ability of PSCs to produce large numbers of human hepatocyte-like cells, with a given or modified genetic background, allows investigators to use previously incompatible experimental techniques, such as high-throughput screens, to enhance our understanding of liver development and disease. In this review, we explore how PSCs have expedited our understanding of developmental mechanisms and have been used to identify new therapeutic options for numerous hepatic diseases. We discuss the future directions of the field, including how to further unlock the potential of the PSC model to make it amenable for use with a broader range of assays and a greater repertoire of diseases. Furthermore, we evaluate the current weaknesses of the PSC model and the directions open to researchers to address these limitations. Conclusion: The use of PSCs to model humanliver disease and development has and will continue to have substantial impact, which is likely to further expand as protocols used to generate hepatic cells are improved.
Authors: Dongsheng Guo; Katelyn Daman; Jennifer Jc Chen; Meng-Jiao Shi; Jing Yan; Zdenka Matijasevic; Amanda M Rickard; Monica H Bennett; Alex Kiselyov; Haowen Zhou; Anne G Bang; Kathryn R Wagner; René Maehr; Oliver D King; Lawrence J Hayward; Charles P Emerson Journal: Elife Date: 2022-01-25 Impact factor: 8.140
Authors: Eleftherios Michailidis; Koen Vercauteren; Liliana Mancio-Silva; Linda Andrus; Cyprien Jahan; Inna Ricardo-Lax; Chenhui Zou; Mohammad Kabbani; Paul Park; Corrine Quirk; Christina Pyrgaki; Brandon Razooky; Lieven Verhoye; Irene Zoluthkin; Wei-Yu Lu; Stuart J Forbes; Luis Chiriboga; Neil D Theise; Roland W Herzog; Hiroshi Suemizu; William M Schneider; Amir Shlomai; Philip Meuleman; Sangeeta N Bhatia; Charles M Rice; Ype P de Jong Journal: Proc Natl Acad Sci U S A Date: 2020-01-08 Impact factor: 11.205
Authors: Gustav Holmgren; Benjamin Ulfenborg; Annika Asplund; Karin Toet; Christian X Andersson; Ann Hammarstedt; Roeland Hanemaaijer; Barbara Küppers-Munther; Jane Synnergren Journal: Int J Mol Sci Date: 2020-01-11 Impact factor: 5.923